Aav vector treatment methods for late infantile neuronal ceroid lipofuscinosis type 2
WO2020102753A1
In vitro assay for detecting enhancers and inhibitors of adeno associated virus (aav) vector transduction and/or detecting or quantitating anti-aav binding antibodies
WO2020102740A2
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
WO2020041773A1
Optimized promoter sequences, intron-free expression constructs and methods of use
EP3794043A1
Codon-optimized acid alpha-glucosidase expression cassettes and methods of using same
WO2019217483A1
Plasmid free aav vector producing cell lines
WO2019210267A2
Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
WO2019126222A1
Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of use
PE20200722A1
METHODS OF GENE THERAPY OF FACTOR VIII (FVIII)
CA3069880A1
Apheresis methods and uses
PE20200737A1
AAV VECTOR COLUMN PURIFICATION METHODS
AU2018281306A1
Enhancing agents for improved cell transfection and/or rAAV vector production
MX2019005334A
Rab escort protein potency assay.
CN110121356A
The method and carrier for treating CNS disease
WO2018017956A2
Scalable high recovery methods for producing high yield recombinant adeno-associated viral (raav) vector and recombinant adeno-associated viral (raav) vectors produced thereby
CN109689033A
The relative effectivenes of coding of the viral vectors isomery hydrolysis alcohol measure
KR20190006951A
Column-based fully scalable rAAV manufacturing process
CN109563496A
The cell line produced for recombinant protein and/or viral vectors
MX2018006682A
Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use.
AU2016344030A1
CpG reduced factor VIII variants, compositions and methods and uses for treatment of hemostasis disorders
